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good as its weakest end point because all
outcomes are treated as having equal value.
It is no surprise that the composite end
point used by Caputo and colleagues is
largely dependent on the presence of recur-
rent angina, which is responsible for 31 of
43 clinical events in the RITA group and
10 of 15 clinical events in the RA group.
There were no objective criteria set for
diagnosing “recurrent angina,” which is al-
ways a difficult end point to assess in clin-
ical trials. The clinical wisdom and validity
of assigning the same statistical weight to
angina and death defy common sense, be-
cause most patients would value the 2 quite
differently.
The duration of follow-up in the study
of Caputo and colleagues2 is short, a me-
dian of 1.8 years for the patients receiving
a RITA graft and only 1.5 years for those
receiving an RA graft. It is clear that this is
a short-term study result and thus more
likely to reflect perioperative factors rather
than the development of graft disease.7 The
study is too short to make any long-term
conclusions. In our randomized trial,1 the
number of patients who had reached 5
years follow-up was relatively small, and
therefore longer-term conclusions are also
limited. A more appropriate conclusion for
the study of Caputo and colleagues would
be that, in the short term, the RITA used as
an in situ pedicle graft to the right coronary
system seems to result in an inferior clini-
cal outcome when compared with the RA.
Caputo and colleagues2 attempted to
control analytically for confounding fac-
tors. In the Cox proportional hazards model
for mortality, this means they were at-
tempting to adjust for other explanatory
variables with very small effective sample
sizes (1 death in the RA group and 5 deaths
in the RITA group). Such an analysis is
ambitious, to say the least. An alternative
form of analysis, which would probe the
comparability of the groups in terms of
their profiles, would be to use the propen-
sity score approach.8 This would model the
surgeon’s choice of operation in terms of
explanatory variables at the time of the
operation. It could show that there are non-
comparable subsets of the patient groups
and would more generally permit an anal-
ysis that more closely mimicked a random-
ized trial than analyses based on modeling
the outcomes in terms of all the explana-
tory variables.
In light of these observations, we be-
lieve that a more balanced conclusion
should have highlighted the limitations of
using composite outcomes to increase sta-
tistical power and raised the possibility that
an in situ RITA graft placed in the right
coronary system, at least in the short term,
might result in inferior results. It should
have also emphasized that these observa-
tions cannot be extrapolated to include free
RITA grafts (used in only 6% of patients)
or in situ RITA grafts placed in the left
system, where many remain patent for
more than 20 years.
There are satisfactory existing data to
guide current surgical practice, but obvi-
ously the long-term results from trials of
prospectively randomized patients are re-
quired.
Brian F. Buxton, MD
Rinaldo Bellomo, MD
Ian Gordon, PhD, AStat
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Reply to the Editor:
In this issue, Buxton and colleagues com-
ment on 2 recent articles in the Journal
reporting evidence about the effects of
choosing the right internal thoracic artery
(RITA) or radial artery (RA) for the second
arterial conduit for bypass grafting. The 2
articles reported interim results of a ran-
domized controlled trial (RCT)1 and a non-
randomized study (NRS).2
Buxton and colleagues advance several
alternative explanations to reconcile the ap-
parently conflicting findings of the two
studies: (1) There were differences in study
design, that is, the greater susceptibility, in
general, of observational data to bias. (2)
Specifically, there was the possibility of
inadequate control in the observational
study for differences between groups in
graft site and grafting strategy. (3) There
was a short duration of follow-up in the
observational study. (4) A composite out-
come (survival free from cardiac-related
events) was used in the observational
study. (5) The findings are, in fact, consis-
tent with one another given the imprecision
of the findings of both studies.
In the absence of data from well-con-
ducted RCTs with sufficient duration of
follow-up, it is not possible to distinguish
between these options; the last one is, argu-
ably, the most parsimonious. As we stated,2
such a trial is the only way to answer the
question, and Buxton and colleagues agree
with this point of view. However, the stated
suggestions raise a number of methodologic
points that may be of interest to readers.
The respective merits of RCTs and
NRSs are debated almost as “hotly” as
those of the RITA and RA.3 If an NRS of
an intervention suggests useful benefits for
patients, the intervention should be further
investigated in an RCT whenever possible.
RCTs and NRSs differ primarily with re-
spect to their susceptibility to selection
bias, leading to potential confounding.3 In
an NRS, the likely direction of confound-
ing can be inferred by inspecting the dis-
tribution of prognostic factors across
groups. If patients who received the appar-
ently more beneficial intervention had
more favorable prognostic characteristics,
then the finding may be explained by con-
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founding; “adjusting” the results (whether
by stratification, conventional multiple re-
gression modeling, or regression modeling
of propensity scores) can never wholly re-
move the effect of confounding, although
adjustment would be expected to weaken
the effect estimates (ie, move the estimates
closer to no benefit). However, if patients
who received the apparently more benefi-
cial intervention had less favorable prog-
nostic characteristics, then the finding is
unlikely to be explained by confounding;
“adjusting” the results will still not wholly
remove the effect of confounding, but ad-
justment would be expected to strengthen
the effect estimates (ie, move the estimates
further away from no benefit).
RITA and RA grafts may be used to
revascularize different sites (circumflex or
right coronary) and in different ways (in
situ or pedicle grafts). In our observational
study, we recognized that grafts to the right
coronary artery are more prone to failure
and carefully controlled the analysis for
site of graft. However, we did not control
for the specific ways in which the conduits
were grafted. Whether one should do so
depends on the extent to which a surgeon’s
preferred grafting strategy is attributable to
the properties of the conduit being grafted.
We regard differences in the way that the
two conduits are grafted as aspects of the
overall strategies of using the RA or RITA
as arterial conduits.
The power of survival analyses is a
function of the number of events observed
(eg, deaths or cardiac-related events). The
number of events is increased both by the
number of subjects and the duration of fol-
low-up. Despite a median duration of fol-
low-up of only approximately 1.5 years in
the NRS,2 compared with 2.5 years in the
interim analysis of the RCT,1 the former
analysis of survival free from cardiac-re-
lated events had considerably more power.
It is not clear to us why using a com-
posite outcome should invalidate the find-
ings of the NRS or why Buxton and col-
leagues criticize this practice, because they
used it themselves (they reported cardiac
event-free survival and mortality alone, as
we did). In our study, the cardiac-related
“event” of recurrent angina was assigned
with reference to the findings of exercise
tolerance tests in exactly the same way for
both groups, thereby minimizing bias as far
as possible. Combining events hierarchi-
cally is the recognized way to analyze mul-
tiple events that may be attributable to the
underlying condition and that may be af-
fected by the interventions being com-
pared. This practice has been used in the
analysis of many internationally renowned
RCTs, for example, combining mortality
and nonfatal myocardial infarction4,5 and
mortality and heart failure.6 It is likely to
be important when mortality is rare, or
when mortality does not reflect outcomes
that are important to patients7; there is pre-
sumably no argument that recurrent angina
matters to patients. The issue of key impor-
tance is the avoidance of differential bias in
the assessment of events. Results are typi-
cally shown for events in a hierarchy of
severity, for example, actuarial survival and
cardiac event-free survival. Participants in a
study who die should not be censored or
omitted from analyses of cardiac event-free
survival, except in special circumstances.
There is a danger that research groups
become entrenched in their views about the
likely answer to a research question before
appropriate evidence becomes available.
We emphasize that this is not our position
and that we were careful in our criticism8
of the interim report of the RCT1 to restrict
our comments to technical points. It is per-
haps unfortunate that the two articles ap-
peared at a similar time. Before performing
our retrospective analysis, we had no prior
expectation that the RA would be better;
rather, we were concerned to ensure that
patients receiving RA grafts were not being
disadvantaged, as suggested by many other
researchers. We believe that our observa-
tional analysis suggests that using the RA
instead of the RITA may have benefits for
patients, and that the benefits may be large;
these are exactly the circumstances in
which the surgical community should col-
laborate to perform a definitive RCT.
Barnaby Reeves, PhD
Massimo Caputo, MD
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The excellent article written by Leyh and
colleagues motivated this letter.1 We hope
to share some of our extensive experience
with methylene blue (MB). It is important
to observe that Leyh and colleagues exam-
ined the results of MB therapy for norepi-
nephrine refractory vasoplegia “after car-
diopulmonary bypass (CPB),” although
this kind of situation may happen before
and even during CPB.
Our ongoing laboratory experiments
have proved the usual safe doses of MB in
regard to possible endothelium dysfunc-
tion. We have performed studies in porcine
arteries (coronary, renal, superior mesen-
teric, and hepatic), rabbit aortas, and canine
femoral arteries. By comparing sham ani-
mals with animals that received intrave-
nous (IV) MB, we found differences only
in intermediary concentrations in dose-re-
sponse curves to the calcium ionophore
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